This study examines the Food and Drug Administration’s accelerated approval pathway and whether preapproval initiation was associated with faster conversion to traditional approval or withdrawal for drugs with nononcology indications.
No takes yet. Share an insight, caveat, or question.
Shahzad et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: